Key result
Ultrafiltration and peritoneal dialysis represent relevant options for managing congestion in ADHF and chronic CRS.
Why the study?
Heart failure causes high morbidity and mortality, and suboptimal responses to diuretic-based regimens in renal venous congestion have positioned ultrafiltration and peritoneal dialysis as therapeutic options.
This review discusses the pathophysiologic basis and clinical trial evidence for ultrafiltration and peritoneal dialysis in managing congestion in heart failure.
May support congestion management in select cardiorenal cases; leaves open need for definitive RCTs.
BACKGROUND: Heart failure remains a significant public health burden given its prevalence, morbidity, mortality as well its untoward financial consequences. SUMMARY: The assessment of congestion and its treatment are integral in heart failure pathophysiology and outcomes. Renal venous congestion and its suboptimal response to diuretic-based and novel pharmacological therapeutic regimens have thus positioned ultrafiltration as a promising therapeutic option for patients with acute decompensated heart failure. As a corollary, peritoneal dialysis has had success establishing itself as a relevant therapeutic option for chronic cardiorenal syndrome in patients with heart failure. KEY MESSAGES: Herein, we will discuss the pathophysiologic basis of ultrafiltration and peritoneal dialysis in heart failure with a review of the relevant clinical trials on safety and efficacy profiles in these patient populations.
No takes yet. Share an insight, caveat, or question.
Belal et al. (2024) conducted a review in Heart failure. Ultrafiltration and peritoneal dialysis was evaluated. Ultrafiltration and peritoneal dialysis are discussed as relevant therapeutic options for managing congestion in acute decompensated heart failure and chronic cardiorenal syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: